New diabetes drug enters testing against popular treatment
Disease control
Not yet recruiting
This study is testing a new injectable medication called PG-102 for people with type 2 diabetes. Researchers will compare PG-102 against a placebo (inactive treatment) and an existing diabetes drug called semaglutide over 24 weeks. The main goals are to see if PG-102 safely lower…
Phase: PHASE2 • Sponsor: ProGen. Co., Ltd. • Aim: Disease control
Last updated Apr 02, 2026 06:57 UTC